(Q34921317)

5 August 2017

1 reference

title

Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib (English)

1 reference

5 August 2017

1 reference

Janice N Cormier

1

1 reference

5 August 2017

Shreyaskumar R Patel

series ordinal

2

1 reference

5 August 2017

Peter W T Pisters

series ordinal

3

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

published in

Current Oncology Reports

1 reference

5 August 2017

volume

4

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

504-509

1 reference

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0064-5

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0064-5

Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0064-5

Activating c-kit gene mutations in human germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-002-0064-5

Gastrointestinal stromal tumors

21 January 2018

1 reference

12 December 2020

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

12 December 2020

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

12 December 2020

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

1 reference

12 December 2020

STI571: a paradigm of new agents for cancer therapeutics

1 reference

12 December 2020

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastr

1 reference

12 December 2020

Identification of a ligand for the c-kit proto-oncogene

1 reference

12 December 2020

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells.

1 reference

12 December 2020

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Chronic myeloid leukemia

1 reference

12 December 2020

Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand

1 reference

12 December 2020

Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia

1 reference

12 December 2020

Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal

1 reference

12 December 2020

Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis

1 reference

12 December 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

12 December 2020

Imatinib mesylate--a new oral targeted therapy

1 reference

12 December 2020

Stem cell factor and hematopoiesis

1 reference

12 December 2020

CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34.

1 reference

12 December 2020

Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

1 reference

12 December 2020

The biology of chronic myeloid leukemia

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor

1 reference

12 December 2020

Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours

1 reference

12 December 2020

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors

1 reference

12 December 2020

Coexpression of stem cell factor and c-kit in embryonic and adult liver

1 reference

12 December 2020

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

12 December 2020

Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

Gastrointestinal stromal tumors: recent advances in understanding of their biology

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options

1 reference

12 December 2020

10.1007/S11912-002-0064-5

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1014551100

0 references

1 reference